These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11689635)

  • 1. Unique monoclonal antibody recognizing the third extracellular loop of CXCR4 induces lymphocyte agglutination and enhances human immunodeficiency virus type 1-mediated syncytium formation and productive infection.
    Tanaka R; Yoshida A; Murakami T; Baba E; Lichtenfeld J; Omori T; Kimura T; Tsurutani N; Fujii N; Wang ZX; Peiper SC; Yamamoto N; Tanaka Y
    J Virol; 2001 Dec; 75(23):11534-43. PubMed ID: 11689635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of an unique CXCR4 epitope whose ligation inhibits infection by both CXCR4 and CCR5 tropic human immunodeficiency type-I viruses.
    Adachi T; Tanaka R; Kodama A; Saito M; Takahashi Y; Ansari AA; Tanaka Y
    Retrovirology; 2011 Oct; 8():84. PubMed ID: 22018245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the leukocyte function antigen-1 conformational state in the process of human immunodeficiency virus type 1-mediated syncytium formation and virus infection.
    Fortin JF; Barbeau B; Hedman H; Lundgren E; Tremblay MJ
    Virology; 1999 Apr; 257(1):228-38. PubMed ID: 10208936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence as a HIV-1 self-defense vaccine of cyclic chimeric dodecapeptide warped from undecapeptidyl arch of extracellular loop 2 in both CCR5 and CXCR4.
    Misumi S; Takamune N; Ido Y; Hayashi S; Endo M; Mukai R; Tachibana K; Umeda M; Shoji S
    Biochem Biophys Res Commun; 2001 Aug; 285(5):1309-16. PubMed ID: 11478800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity.
    Khurana S; Kennedy M; King LR; Golding H
    J Virol; 2005 Jun; 79(11):6791-800. PubMed ID: 15890918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of multiclade R5 and X4 human immunodeficiency virus type-1 infections by a coreceptor-based anti-HIV strategy.
    Nakayama D; Misumi S; Mukai R; Tachibana K; Umeda M; Shibata H; Takamune N; Shoji S
    J Biochem; 2005 Nov; 138(5):571-82. PubMed ID: 16272569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CXCR4 monoclonal antibodies recognizing overlapping epitopes differ significantly in their ability to inhibit entry of human immunodeficiency virus type 1.
    Carnec X; Quan L; Olson WC; Hazan U; Dragic T
    J Virol; 2005 Feb; 79(3):1930-3. PubMed ID: 15650218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralising properties of peptides derived from CXCR4 extracellular loops towards CXCL12 binding and HIV-1 infection.
    Chevigné A; Fievez V; Szpakowska M; Fischer A; Counson M; Plesséria JM; Schmit JC; Deroo S
    Biochim Biophys Acta; 2014 May; 1843(5):1031-41. PubMed ID: 24480462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in mast cell function and survival following in vitro infection with human immunodeficiency viruses-1 through CXCR4.
    Taub DD; Mikovits JA; Nilsson G; Schaffer EM; Key ML; Petrow-Sadowski C; Ruscetti FW
    Cell Immunol; 2004 Aug; 230(2):65-80. PubMed ID: 15598422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
    Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
    J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An anti-LFA-1 monoclonal antibody (LDA-8) induces cellular aggregation of human lymphoblastoid cell lines and peripheral blood lymphocytes.
    Yang JS; Mathioudakis G; Kruzel E; Angelo LS; Sakkas LI; Lee JE; Oleszak EL; Platsoucas CD
    Hematopathol Mol Hematol; 1997-1998; 11(1):29-40. PubMed ID: 9439978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of CXCR4-dependent HIV-1 infection by extracellular HIV-1 Tat.
    Ghezzi S; Noonan DM; Aluigi MG; Vallanti G; Cota M; Benelli R; Morini M; Reeves JD; Vicenzi E; Poli G; Albini A
    Biochem Biophys Res Commun; 2000 Apr; 270(3):992-6. PubMed ID: 10772939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.
    Labrosse B; Treboute C; Brelot A; Alizon M
    J Virol; 2001 Jun; 75(12):5457-64. PubMed ID: 11356952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The carboxyl-terminal region of HIV-1 Nef protein is a cell surface domain that can interact with CD4+ T cells.
    Otake K; Fujii Y; Nakaya T; Nishino Y; Zhong Q; Fujinaga K; Kameoka M; Ohki K; Ikuta K
    J Immunol; 1994 Dec; 153(12):5826-37. PubMed ID: 7989778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ELDKWA-epitope-specific monoclonal antibodies inhibit HIV env-mediated syncytium formation.
    Zhang G; Chen YH
    Immunobiology; 2003; 207(4):259-64. PubMed ID: 12952348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of human immunodeficiency virus type 1-induced syncytium formation by the conformational state of LFA-1 determined by a new luciferase-based syncytium quantitative assay.
    Barbeau B; Fortin JF; Genois N; Tremblay MJ
    J Virol; 1998 Sep; 72(9):7125-36. PubMed ID: 9696806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic appearance of antigenic epitopes effective for viral neutralization during membrane fusion initiated by interactions between HIV-1 envelope proteins and CD4/CXCR4.
    Toda T; Kuwahara K; Kondo N; Matsuda Z; Maeda Y; Maeda K; Sakaguchi N
    Immunobiology; 2012 Sep; 217(9):864-72. PubMed ID: 22226668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and delineation of CXCR-4 (fusin) as an entry and fusion cofactor for T-tropic [correction of T cell-tropic] HIV-1 by three different monoclonal antibodies.
    Hori T; Sakaida H; Sato A; Nakajima T; Shida H; Yoshie O; Uchiyama T
    J Immunol; 1998 Jan; 160(1):180-8. PubMed ID: 9551970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.